Trial Watch: Peptide-based anticancer vaccines
| Autor: | Jonathan Pol, Norma Bloy, Aitziber Buqué, Alexander Eggermont, Isabelle Cremer, Catherine Sautès-Fridman, Jérôme Galon, Eric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
immunostimulatory cytokines
TRA tumor rejection antigen Immunology Context (language use) Peptide HPV human papillomavirus Review Biology survivin IFNα interferon α TAA tumor-associated antigen Immune system Murine tumor Antigen IL-2 interleukin-2 MUC1 mucin 1 Immunology and Allergy Malignant cells PPV personalized peptide vaccination IDH1 isocitrate dehydrogenase 1 (NADP+) soluble chemistry.chemical_classification Hpv human papillomavirus CMP carbohydrate-mimetic peptide carbohydrate-mimetic peptides SLP synthetic long peptide IDO1 indoleamine 2 3-dioxygenase 1 PADRE pan-DR binding peptide epitope synthetic long peptides FDA Food and Drug Administration immune checkpoint blockers WT1 EGFR epidermal growth factor receptor TERT telomerase reverse transcriptase GM-CSF granulocyte macrophage colony stimulating factor Oncology chemistry APC antigen-presenting cell Tumor rejection NSCLC non-small cell lung carcinoma TLR Toll-like receptor |
| Zdroj: | Oncoimmunology ResearcherID |
| ISSN: | 2162-402X 2162-4011 |
| Popis: | Malignant cells express antigens that can be harnessed to elicit anticancer immune responses. One approach to achieve such goal consists in the administration of tumor-associated antigens (TAAs) or peptides thereof as recombinant proteins in the presence of adequate adjuvants. Throughout the past decade, peptide vaccines have been shown to mediate antineoplastic effects in various murine tumor models, especially when administered in the context of potent immunostimulatory regimens. In spite of multiple limitations, first of all the fact that anticancer vaccines are often employed as therapeutic (rather than prophylactic) agents, this immunotherapeutic paradigm has been intensively investigated in clinical scenarios, with promising results. Currently, both experimentalists and clinicians are focusing their efforts on the identification of so-called tumor rejection antigens, i.e., TAAs that can elicit an immune response leading to disease eradication, as well as to combinatorial immunostimulatory interventions with superior adjuvant activity in patients. Here, we summarize the latest advances in the development of peptide vaccines for cancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|